SU-E-T-569: Evaluation of VMAT Plans Generated with HD120 and Millennium 120 MLC Between Two Matched Linacs

Authors


Abstract

Purpose:

To evaluate VMAT treatment plans generated with HD120 MLC and Millennium 120 MLC between two matched linacs and to determine if one can back up the other.

Methods:

The 6x photon beams are matched for our Varian TrueBeam STx and Trilogy linacs, which are equipped with HD120 MLC and Millennium 120 MLC, respectively. Three prostate and three brain VMAT plans were used for the evaluation. Five plans (three prostate and two brain plans) were originally generated with the TrueBeam STx and re-computed with the Trilogy. One brain plan was evaluated the other way around. For each plan, the PTV coverage of V95 was made the same between two linacs. The dosimetric differences associated with the plans were compared using: 1) Percentage mean dose differences to the PTV, 2) Homogeneity index, HI = (Dmax − Dmin)/Dmean for the PTV. For prostate plans, the mean dose differences to the rectum were evaluated. While for brain plans, the percentage max dose differences to the lenses (left and right lens) were evaluated.

Results:

For three prostate plans, the average of the percentage mean dose differences to the PTV was 0.5 ± 0.1% and the HI was 0.1 ± 0.0%. The average of the percentage mean dose difference to the rectum was 3.5 ± 0.5%. For three brain plans, the average of the percentage mean dose differences to the PTV was 0.2 ± 1.1% and the HI was 0.2 ± 0.1%. The average of the percentage max dose differences to the lenses was 22.9 ± 4.0%.

Conclusion:

For prostate VMAT plans, changing the treatment from the TrueBeam STx to the Trilogy does not necessarily need re-optimization. But for brain plans, in order to minimize dose to the lenses, it is recommended to re-optimize the plan if changing the treatment between these two linacs.

Ancillary